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Chitin hydrolases have been identified in a variety of
organisms ranging from bacteria to eukaryotes. They
have been proposed to be possible targets for the design
of novel chemotherapeutics against human pathogens
such as fungi and protozoan parasites as mammals were
not thought to possess chitin-processing enzymes. Re-
cently, a human chitotriosidase was described as a
marker for Gaucher disease with plasma levels of the
enzyme elevated up to 2 orders of magnitude. The chi-
totriosidase was shown to be active against colloidal
chitin and is inhibited by the family 18 chitinase inhib-
itor allosamidin. Here, the crystal structure of the hu-
man chitotriosidase and complexes with a chitooligosac-
charide and allosamidin are described. The structures
reveal an elongated active site cleft, compatible with the
binding of long chitin polymers, and explain the inacti-
vation of the enzyme through an inherited genetic defi-
ciency. Comparison with YM1 and HCgp-39 shows how
the chitinase has evolved into these mammalian lectins
by the mutation of key residues in the active site, tuning
the substrate binding specificity. The soaking experi-
ments with allosamidin and chitooligosaccharides give
insight into ligand binding properties and allow the
evaluation of differential binding and design of species-
selective chitinase inhibitors.
Family 18 chitinases hydrolyze chitin, an abundant polymer
of N-acetylglucosamine (NAG).1 These enzymes have been
identified in bacteria (1), fungi (2), insects (3), plants (4), vi-
ruses (5), and protozoan parasites (6). Humans were thought
not to possess or process chitin, and therefore chitinases have
been proposed to be targets for the development of inhibitors
with chemotherapeutical potential as insecticides, fungicides,
and antimalarials (6–9). Recently, however, it was discovered
that humans have a chitinase activity that was found to be
elevated up to 2 orders of magnitude in the plasma of patients
suffering from Gaucher disease, a rare genetic disorder that is
caused by a mutation in the glucocerebrosidase gene (10, 11).
Purification of this activity from a Gaucher spleen revealed
that, although transcribed from a single gene, the enzyme
occurs in two major forms of 39 and 50 kDa. The subsequent
cloning of its cDNA from a macrophage library showed that the
50-kDa form can be converted to the 39-kDa form post-trans-
lationally or by RNA processing (12–15). The enzyme is able to
cleave chitotriose (and was termed chitotriosidase) but also
hydrolyzes colloidal chitin to yield chitobiose and is thus
thought to be an exochitinase (12, 16). Although the 39-kDa
form is sufficient for the chitinolytic activity, the additional
C-terminal domain has been shown to play a role in processing
colloidal chitin and has been proposed to be a chitin binding
domain, similar to other domains observed in the structures of
chitinase A/B from Serratia marcescens (14, 17, 18). The chito-
triosidase gene appears not to be essential, as about 35% of
humans are heterozygous (6% homozygous) for an inactivated
form of the gene (11, 15).
Although the enzyme has been characterized in detail, its
function has not been fully defined. The observations that it is
able to degrade both colloidal chitin and chitin in the cell wall
of the fungal pathogen Candida albicans have prompted the
hypothesis that the chitotriosidase plays a role in defense
against chitinous human pathogens (15, 16). Indirect support
for this hypothesis has recently come from a study showing
that humans deficient in chitotriosidase activity are more sus-
ceptible to nematodal infections (19). Parasitic nematodes syn-
thesize chitin during several stages of their lifecycle, and a
human chitotriosidase could interfere with these processes.
Thus, although the chitotriosidase is not essential from a gen-
eral metabolic point of view, it may play a key role as a patho-
gen-defense protein. This implies that although chitinases in
the pathogenic organisms themselves may be targets for the
design of small molecule inhibitors with chemotherapeutical
potential, it would be beneficial to exclude inhibitors that show
strong activity against the human chitotriosidase. The most
potent inhibitor currently known, the pseudotrisaccharide al-
losamidin (3), inhibits all family 18 chitinases with Ki values in
the nanomolar to micromolar range, the human enzyme being
inhibited at a Ki of 0.4 M (16).
Here, we describe the crystal structures of human chitotrio-
sidase in two crystal forms (at 2.35- and 2.1-Å resolution), a
complex with chitobiose, and a soaking experiment with allosa-
midin. The chitotriosidase structure provides insight into the
molecular basis of the inherited genetic inactivation of the
enzyme and the evolution of the chitinase to form a structural
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scaffold for several mammalian lectins. By comparison of the
active site with that of chitinases from pathogenic organisms,
we show that it should be possible to design allosamidin deriv-
atives or other small molecules that are selective inhibitors.
MATERIALS AND METHODS
Purification and Crystallization—Human recombinant chitotriosi-
dase was purified from the medium of stably transfected baby hamster
kidney cells using the full-length human chitotriosidase cDNA cloned in
the pNUT vector (20). 1.5 mg of freeze-dried human chitinase was
dissolved in 6 ml of 50 mM Tris/HCl, pH 8.7, and dialyzed against 1 liter
of the same overnight at 4 °C. It was then spin-concentrated to 7.7
mg/ml. Vapor diffusion crystallization experiments were set up by mix-
ing 0.5 l of protein with an equal volume of 0.1 M Tris/HCl, pH 8.5, 30%
PEG 4000. After 5 weeks of equilibration at room temperature, rod-
shaped crystals grew to a size of 0.1  0.1  0.2 mm. Crystals were
cryoprotected by a 10-s immersion in mother liquor with 15% PEG 2000
monomethylether and then frozen in a 100 K nitrogen gas stream. They
belonged to space group P43212 with cell parameters a  b  93.26 Å,
and c  89.80 Å, with one protein molecule present per asymmetric
unit.
Monoclinic chitotriosidase crystals were obtained at room tempera-
ture by mixing 5 l of protein solution (10 mg/ml) with an equal volume
of 0.1 M citrate buffer, pH 5.6, 24–27% PEG 3350, and 40% ethylene
glycol. Crystals grew as plates to a size of 0.1  0.2  0.05 mm. The
crystals were directly flash-frozen in a 100 K nitrogen stream. They
belong to space group P21 with cell parameters a  45.17 Å, b  47.29
Å, c  84.73 Å, and   102.58o with one molecule in the asymmetric
unit.
Crystals grown under slightly different conditions (0.1 M Tris/HCl,
pH 9.0, 0.2 M Li2SO4, 32.5% PEG 4000, 20 °C) were used for soaks with
allosamidin by the addition of 0.25 l of a 50 mg/ml solution. The
addition of the inhibitor resulted in severe cracking of the crystals. The
soaked crystals were cryoprotected by a 10-s immersion in mother
liquor with 10% glycerol and then frozen in a 100 K nitrogen gas
stream.
Larger (1.0  0.1  0.1 mm) native tetragonal crystals of chitotrio-
sidase could be obtained using a solution of 0.1 M citrate buffer, pH 5.6,
0.2 M ammonium acetate, 24–27% PEG 3350 as a precipitant. These
crystals were soaked for 1 h at room temperature in 5 mM NAG5 (N
I,
NII, NIII, NIV, NV-pentaacetylchitopentaose, Sigma), 0.1 M CAPS buffer,
pH 10.6, 0.2 M ammonium acetate, 30% PEG 3350. Before soaking, the
crystals were transferred from the mother liquor to the final solution by
gradually increasing the pH.
Data Collection, Structure Solution, and Refinement—Data for the
P43212 crystals and allosamidin soaks were collected on beamlines
ID14–1 and ID29 at the European Synchrotron Radiation Facility on
Quantum-Q4 and Quantum-Q210 detectors, respectively. Data for the
P21 crystals and P43212 crystals soaked with NAG5 were collected on an
ENRAF-Nonius rotating anode with a MacScience DIP2030 image plate
detector and at the ELETTRA synchrotron, Trieste, Italy on a MAR345
image plate detector, respectively (Table I). Data were processed with
the HKL suite (21).
The native structure was solved in space group P43212 by molecular
replacement with AMoRe (22), using the structure of the lectin YM1
(23) as a search model, against 8–4-Å data. A clear solution was
obtained (r  0.418, correlation coefficient of 0.50). The model was then
refined by iterative model building in O (24) and refinement in CNS (25)
using a small set of reflections for calculation of Rfree (Table I). A
complete structure was obtained for residues Ala-22 to Leu-385, al-
though residues 232–234 in a solvent-exposed loop could not be modeled
due to disorder. The final model has an R-factor of 0.216 (Rfree  0.262).
98.7% of the residues are in allowed regions of the Ramachandran plot,
and 1.3% are in “generously allowed” (three residues) or disallowed (one
residue, Asp-278, in a less well defined loop) regions, according to the
PROCHECK definitions (26). At a later stage, a second crystal form, in
space group P21, was obtained from ethylene glycol solutions and was
solved by molecular replacement using the P43212 structure as a search
model. Refinement and model building were performed as described
above and resulted in a final model as outlined in Table I.
A complex of the chitotriosidase with NAG2 was obtained by soaking
crystals in P43212 in NAG5 (see above). Refinement revealed well or-
dered density in the active site corresponding to an N-acetylglu-
cosamine dimer (see Fig. 1B), which was built and included in further
refinement (see Table I).
Attempts to obtain a well defined chitotriosidase-allosamidin com-
plex were hampered by cracking of allosamidin-soaked crystals, result-
ing in high mosaicity (varying from 0.9 to2°) and rather large changes
in unit cell dimensions (Table I). Here, we only use the unbiased Fo 
Fc, calc map at 2.7 Å (see Fig. 3B) after one round of refinement to
confirm a model of the chitotriosidase-allosamidin complex constructed
by superposition of the chitotriosidase with previously published chiti-
nase-allosamidin complexes (27–29). All images were generated with
PyMOL (www.pymol.org). Structural superpositions were performed
with the MOTIF module in WHAT IF (30).
RESULTS AND DISCUSSION
Overall Structure and Interaction with Chitin—The struc-
ture of the 39-kDa form of human chitotriosidase was solved by
molecular replacement and refined against 2.35-Å diffraction
data to an R-factor of 0.216 (Rfree  0.262) in space group
P43212 with good stereochemistry (Table I, Fig. 1). The struc-
ture consists of two domains. The core domain has a (/)8
barrel as observed in the other family 18 chitinase structures
for hevamine (31), chitinases A (ChiA) (17) and B (ChiB) (18)
TABLE I
Details of data collection and structure refinement for native chitotriosidase and complexes
Values between brackets are for the highest resolution shell. All measured data were included in structure refinement.
Native I Native II NAG5 Allosamidin
Space group P43212 P21 P43212 P43212
Cell dimensions (Å) a  93.26 a  45.17 a  94.40 a  98.37
b  93.26 b  47.29 b  94.40 b  98.37
c  89.80   102.6°, c  84.73 c  87.98 c  88.15
Resolution range (Å) 17–2.35 13.4–2.1 35–2.78 30–2.7
(2.43–2.35) (2.15–2.1) (2.88–2.78) (2.8–2.7)
No. observed reflections 95454 (9001) 73055 (4290) 56839 (4190) 35543 (3335)
No. unique reflections 17192 (1670) 20533 (1330) 10485 (916) 11398 (1104)
Redundancy 5.6 (5.4) 3.6 (3.2) 5.4 (4.6) 3.1 (3.0)
I/I 11.1 (3.9) 14.3 (4.6) 15.0 (3.4) 6.3 (2.4)
Completeness (%) 99.8 (99.9) 99.6 (97.0) 97.8 (87.2) 98.5 (98.1)
Rmerge (%) 8.3 (55.3) 7.2 (22.5) 10.6 (45.5) 12.1 (37.2)
Rcryst (%) 21.6 20.4 19.7
Rfree (%) 26.2 22.7 26.9
No. Rfreereflections 545 2077 1042
No. protein atoms 2820 2797 2864
No. water molecules 273 201 17
Refined carbohydrate none none NAG2
R. M. S. deviations from ideal geometry:
bonds (Å) 0.009 0.005 0.007
angles (°) 1.4 1.2 1.2
Bprot (Å
2) 37.8 19.1 48.5
Bcarbohydrate (Å
2) 48.8
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FIG. 1. Overview of chitotriosidase structure and comparison with other chitinases. A, stereo image of the final human chitotriosidase
structure. The backbone is shown as a gray ribbon. The / domain is colored blue. Residues 344–372, which are deleted in the inherited mutated
form of the enzyme, are colored green. Asp-136, Asp-138, and Glu-140 are shown as a sticks model with carbons colored yellow. Solvent-exposed
aromatic side chains lining the active site cleft are shown as purple sticks. NAG2, as seen in the complex (Table I), is shown in a sticks
representation with orange carbon atoms. B, stereo image of the active site. The chitotriosidase backbone is shown as a gray ribbon. Solvent-
exposed aromatics and residues interacting with NAG2 are shown as sticks with carbons colored green for the apo structure and carbons colored
purple for the chitotriosidase-NAG2 complex. A simulated-annealing Fo  Fc, calc map for NAG2 as observed in the chitotriosidase-NAG2 complex
is shown in blue, contoured at 3. NAG2 is shown in a sticks representation with orange carbon atoms. C, overall comparison with other chitinases.
Molecular surfaces (calculated with PyMOL) are shown for currently known complexes of chitinases with chitooligosaccharides: hevamine with
NAG3 (31), ChiA with NAG8 (32), ChiB with NAG5 (29), and the human chitotriosidase with a model of NAG9. The TIM barrel core of the enzymes
is orientated as in panel A. The catalytic glutamic acid is colored red, and exposed aromatic side chains lining the active site cleft are colored blue.
The chitooligosaccharides are shown as sticks with green carbons.
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from S. marcescens, and CTS1 from Coccidioides immitis (28),
although helix 1 is missing (Fig. 1A). An additional / do-
main, composed of six antiparallel -strands and one -helix, is
inserted in the loop between strand 7 and helix 7, which
gives the active site a groove character (Fig. 1C). Like all other
family 18 chitinases, the chitotriosidase has the DXDXE motif
at the end of strand 4 with Glu-140 being the catalytic acid
(Figs. 1A and 2). Two disulfide bridges were observed between
Cys-26–Cys-51 and Cys-307–Cys-370, which are also present
in the YM1 structure (23).
The native chitotriosidase structure was also refined using
diffraction data from a second crystal form (space group P21,
Table I). These crystals were obtained by adding 40% ethylene
glycol to the precipitant solution. Ethylene glycol acts as an
inhibitor of chitotriosidase, and the structure shows the pres-
ence of three molecules of ethylene glycol bound in the active
site. One of them is hydrogen-bonded to Asp-138, which is
essential for catalysis in chitinases (27, 29). This ethylene
glycol molecule may inhibit the chitotriosidase by blocking the
side chain of Asp-138 in the native position, preventing the
binding of the substrate (attempts to bind NAG2 failed). The
P43212 and P21 structures are essentially identical and super-
pose with a root mean squares deviation of 0.5 Å on Ca atoms.
In further discussions below, the structure in space group
P43212 will be used when referring to the native human chito-
triosidase structure.
Soaking experiments with chitooligosaccharides NAG3,
NAG4, or NAG5 were carried out at pH 10.6 to prevent acid-
catalyzed hydrolysis of the substrate. Nevertheless, hydrolysis
occurred, and the experiments consistently resulted in electron
density maps where only an ordered N-acetylglucosamine
dimer could be observed, lying in subsites 2 and 1 (Fig. 1B).
The chitotriosidase structure shows little change upon NAG2
binding. The most relevant is the side chain of Asp-138, which
rotates toward the side chain of Glu-140, as seen in other
studies with chitinases (29, 31–33) (Fig. 1B). Other side chains
(Fig. 1B) undergo minor conformational changes, probably re-
quired to accommodate and stabilize the binding of the oligo-
saccharide. At 2.8-Å resolution (Table I), it is not possible to
unambiguously distinguish a boat (as seen in the ChiA-NAG8
(32) and ChiB-NAG5 (29) complexes) from a chair (as seen in
the hevamine-NAG3 complex (31)) conformation in the 1 sub-
site. However, in our complex, the 1 subsite is not occupied,
and we have therefore modeled the 1 sugar in the chair
conformation.
Through superposition of the ChiB-NAG5 complex (29) and
the ChiA-NAG8 complex (32) onto the chitotriosidase-NAG2
structure, a model of a complex with NAG9 can be produced
(Fig. 1C), an approach used before to produce models of chiti-
nase-ligand complexes (18, 28, 33). In the ChiB-NAG5 complex,
the oligosaccharide occupies subsites 2, 1, 1, 2, 3
(where the scissile glycosidic bond is located between sugars
FIG. 2. Sequence alignment of chitinases. Structure-based sequence alignments between the human chitotriosidase (HU_CHTR) and other
closely related structures (mouse YM1 (23) (MM_YM1), chitinase A (17) (SM_CHIA) and B (18) (SM_CHIB) from S. marcescens, and CTS1 from
C. immitis (CI_CTS1) are shown. Also included is the sequence for HCgp-39 (37) (HU_HCGP), which was aligned with CLUSTAL-W (43).
Conserved regions are boxed. The eight -strands in the TIM barrel are indicated and labeled. The long dotted line represents the / domain (see
also Fig. 1). The gray bar indicates the stretch of residues (344–372) deleted in the inherited inactive form of the chitotriosidase. Solvent-exposed
aromatic residues lining the active site cleft are labeled with a black dot. The catalytic glutamic acid in the DXDXE motif (Glu-140 in the
chitotriosidase) is indicated by an arrow.
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1 and 1 (34)), whereas in the ChiA-NAG8 complex, subsites
6 to 2 are occupied (32). In the superpositions, the subsites
2 to 2 are occupied by the chitooligosaccharides from both
the ChiA and ChiB complexes (the 2 to 1 subsites are also
occupied by the chitotriosidase-NAG2 complex), with the sugar
atoms overlapping closely, to form a continuous NAG polymer
from 6 to 3. In this model of the complex, the oxygen in the
scissile glycosidic bond between the 1 and 1 sugars lies
within hydrogen bonding distance (2.9 Å) of the carboxylic
oxygen O2 of the catalytic Glu-140. NAG9 appears to fit the
human chitotriosidase active site cleft without steric hin-
drance. Inspection of the active site lining reveals several sol-
vent-exposed aromatic side chains that stack against the hy-
drophobic face of the sugars (Figs. 1 and 2). The pattern and
conservation of these exposed aromatic residues is most remi-
niscent of that observed in ChiA with the conserved Trp-31 and
Tyr-34 stabilizing the 6 non-reducing end of the bound chitin
oligomer (Figs. 1 and 2). Although the pattern of exposed aro-
matic residues is most homologous to ChiA, the chitotriosidase
has a more compact structure with several shorter loops (Figs.
1 and 2). The most striking difference, however, is that al-
though ChiA has an N-terminal fibronectin type III domain,
which is thought to be important for chitin binding (and has
several exposed aromatic residues, Figs. 1 and 2) (17), the
39-kDa chitotriosidase form does not have such a domain (12).
In contrast, an extra chitin binding domain is present in the
50-kDa form of the enzyme, but interestingly, this is located
toward the C terminus, similar to what is observed in ChiB (18)
(Fig. 1C). The sequence of the domain does not show homology
to known structures, but similarities with the sequences of
similar domains in nematodal and insect chitinases have been
noted (13).
Although the human chitotriosidase has been established to
be a fully active chitinase (11, 12), its precise substrate speci-
ficity has not been defined. The enzyme has been shown to
hydrolyze 4-methylumbelliferyl -D-chitooligosaccharides
(4MU-NAGx) (12) and to reduce various forms of polymeric
chitin to dimers (12, 16), yet the experimental data do not
exclusively classify it as either an endo- or exochitinase.
Inspection of the structure provides some clues. ChiA and
ChiB are both exochitinases and have a deep active site cleft,
which is partially closed by overhanging loops, whereas the
chitotriosidase cleft is more open (Fig. 1C). The ChiA/B active
sites also appear to be blocked at opposite ends (at the re-
ducing end for ChiA and at the non-reducing end for ChiB),
which explains their synergism in the degradation of poly-
meric chitin (1). In contrast, the chitotriosidase active site
cleft appears to be fully extended over one face of the enzyme,
although narrowing somewhat at the far reducing end of the
NAG9 model (Fig. 1C). From a structural point of view, it is
thus possible that the chitotriosidase is an endochitinase.
This would be consistent with its proposed role as a defense
protein against chitin-containing pathogens such as fungi
and its ability to directly degrade chitin from C. albicans cell
walls (12, 13, 16).
Structural Basis for Inherited Chitotriosidase Deficiency—As
mentioned earlier, the chitotriosidase is a marker for Gaucher
disease with plasma levels over 2 orders of magnitude elevated
as compared with healthy control individuals (11). However, in
the same study, it was also noted that about 1 in 20 individuals
was completely deficient in active chitotriosidase (11). Detailed
studies later revealed that this was an inherited genetic defect
due to a 24-base pair duplication in exon 10 (15). This duplica-
tion generates a cryptic splice site, leading to an 87-nucleotide
deletion with significantly decreased mRNA levels (15). Al-
though the mRNA is translated normally, a completely inactive
enzyme is produced with residues Val-344–Gln-372 missing.
The chitotriosidase structure presented here allows us to un-
derstand why deletion of this region inactivates the enzyme.
Figs. 1A and 2 show that residues 344–372 correspond to the
C-terminal half of helix 7, the entire strand 8, and almost
the entire 8-8 loop. Deletion of these secondary structure
elements could lead to misfolded, and therefore inactive, pro-
tein. More importantly perhaps, Trp-358, which lies at the end
of strand 8, is completely conserved in all active family 18
chitinases (Fig. 2). Inspection of chitinase structures in com-
plex with chitooligosaccharides (29, 32) shows that this trypto-
phan serves as an “anvil” onto which the 1 sugar is pressed,
whereas specific hydrogen-bonds with other residues may force
the sugar in the boat conformation required for the attack of
the N-acetyl group on the anomeric carbon (29) (Fig. 1A). Thus,
deletion of Trp-358 could in itself lead to a completely inactive
enzyme.
Comparison with the Mammalian Lectins YM1 and HCgp-
39—Apart from the human chitotriosidase, two other family 18
chitinase-like mammalian proteins have been described re-
cently. YM1 and HCgp-39 both show a high degree of sequence
similarity to family 18 chitinases (23, 35) (Fig. 2). The structure
of YM1 has been determined by x-ray crystallography, reveal-
ing density for a single glucosamine in the active site (23). As
was predicted from multiple sequence alignments (Fig. 2), two
key residues in the active site were mutated (Asp-136 to Asn
and Glu-140 to Gln), which renders the protein completely
inactive as a chitinase. Binding experiments and crystallo-
graphic analysis further showed that YM1 does not interact
with polymeric carbohydrates but rather with monomers (23,
36), although the YM1 structure did not reveal why the chiti-
nase-like protein had lost its ability to interact with carbohy-
drate polymers. The human chitotriosidase structures pre-
sented here allow us to explain this loss of affinity (Fig. 3A).
Apart from the elimination of catalytic activity through the
mutations in the active site, there are several non-conservative
substitutions in the chitin binding cleft. Tyr-24, near the non-
reducing end of the substrate binding cleft, is replaced with an
aspartic acid, whereas the nearby Trp-72 is replaced with a
glutamic acid (Figs. 2 and 3A). On the other side of the cleft,
Trp-218 is changed to a lysine, and Tyr-190 is replaced by the
smaller valine. The trend in these mutations is that almost half
of the exposed aromatic residues, discussed earlier and shown
in Fig. 1, have been non-conservatively replaced, indeed in
most cases with charged amino acids. Thus, although all the
residues required for interaction with monomeric carbohy-
drates are still present in the core of the active site, the cleft-
lining residues required for the binding of polymeric substrate
have been removed. This explains the observed carbohydrate
binding specificity (monomers only) for YM1 (36).
Similar to YM1, the human cartilage protein HCgp-39 has
all the signs of an inactivated chitinase. Although its sequence
suggests a family 18 chitinase-like structure, two key active
site residues, the equivalents of Asp-138 and Glu-140 in the
chitotriosidase, have been mutated to Ala and Leu, respec-
tively, and HCgp-39 does not have detectable chitinase activity
(37). Binding studies, however, have shown that unlike YM1,
HCgp-39 binds chitin with high affinity and has therefore been
proposed to be a chitin-specific lectin (35). A structure for
HCcp-39 is not available. However, sequence alignment shows
that unlike YM1, all of the solvent-exposed aromatics are con-
served in HCgp-39 with the exception of Tyr-190, which is not
a conserved residue in other chitinases either (Fig. 2). Thus,
like the human chitotriosidase, the active site cleft of HCgp-39
would be lined with exposed aromatic residues and could sup-
port the binding of longer chitin oligomers.
Structure of Human Chitotriosidase 25541
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 11, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
FIG. 3. Comparison of active site details and interaction with allosamidin. In A, the substrate binding pockets of the human chitotrio-
sidase and YM1 are compared. Protein backbones are represented by a gray ribbon. A model of NAG9, in equivalent position to that in Fig. 1, is
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Implications for Selective Inhibitor Design—The most potent
chitinase inhibitor currently known is allosamidin, a pseudo-
trisaccharide (consisting of two (1,4)-linked N-acetyl al-
losamine sugars coupled to allosamizoline, Fig. 3B) isolated
from Streptomyces (3, 38). All family 18 chitinases tested are
inhibited by this molecule with Ki values in the nanomolar to
micromolar range (39, 40); it inhibits the chitotriosidase with a
Ki of 0.4 M (16). Allosamidin has been shown to have a fungi-
static effect by interfering with fungal cell separation (2, 9) and
to act as a malaria transmission blocker as it strongly inhibits
a Plasmodium falciparum chitinase required for insect inva-
sion (6, 8). However, the recent implication that the human
chitotriosidase, although not essential from a housekeeping
point of view, may play a role in defense against pathogens (15,
19) suggests that a broad spectrum chitinase inhibitor might
have negative side effects if administered to humans. Thus, if
chitinase inhibitors, such as allosamidin, are further developed
to enhance their fungicidal, insecticidal, and antimalarial po-
tential, inhibition of the human chitotriosidase should be re-
duced to weak levels. We addressed this issue by soaking chi-
totriosidase crystals with allosamidin and positioning the
inhibitor according to a 2.7-Å difference map (Fig. 3B). Com-
parison of this complex with the one obtained for the chitinase
CTS1 from the fungal pathogen C. immitis (28), which is the
causative agent of the respiratory disease known as San
Joaquin Valley fever in the southern Americas, suggests a
strategy for improving the efficacy of antifungal molecules. It is
apparent that the overall shape of the active site in the 1
subsite is nearly identical for the chitotriosidase and CTS1
complexes with allosamidin and also for complexes of the in-
hibitor with hevamine (27) and ChiB (29). The allosamizoline
moiety binds deep in the active site, interacting closely with,
among others, Asp-138 and Trp-358, both completely conserved
in family 18 chitinases (Fig. 2). Only few protein side chains
interact with the allosamine sugars in the 2 and 3 positions
(Fig. 3B), and it is also here that some differences are observed
between the human and fungal enzymes. Asn-100, which hy-
drogen-bonds to the oxygen of the N-acetyl group on the 3
sugar, is replaced by the shorter threonine in the fungal en-
zyme (Fig. 3B). Met-300, which stacks against the methyl of the
N-acetyl group on the 2 sugar, is a valine in the fungal
enzyme, creating a small void (Fig. 3B). Thus, there appears to
be scope for the development of allosamidin derivatives with
differential specificity based on the changes around the2 and
3 subsites. In this context, it is worth noticing that such
derivatives have already been reported, although so far all
changes in the allosamine sugars appear to reduce chitinase
inhibition (39, 41, 42).
Conclusion—The structure of the human chitotriosidase and
its complexes described here have provided further clues for
understanding the possible functions of the protein and its
closely related homologues, YM1 and HCgp-39. The structure
reveals that a long cleft runs across one face of the protein and
that this cleft is lined with solvent-exposed aromatic residues.
This suggests the ability to bind long chitin polymers, and
given the relatively open active site architecture, implies that
chitotriosidase functions as an endochitinase rather than an
exochitinase. The complex with NAG2 followed by modeling of
a longer chitooligosaccharide revealed that the active site
would be able to accommodate longer chitin polymers, which
agrees with its ability to degrade various forms of polymeric
chitin. The human enzyme appears to have significant differ-
ences in the active site as compared with a chitinase from the
pathogenic fungus C. immitis, which may be exploitable in the
design of allosamidin derivatives or other inhibitors that show
differential specificity toward human and pathogen chitinases.
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